当前位置： SCI文献检索 > LEUKEMIA & LYMPHOMA期刊下所有文献 > Tocilizumab, in search for a role in acute GVHD.

Tocilizumab, in search for a role in acute GVHD.

Abstract：

:Acute graft versus host disease (aGVHD) was first described by Barnes et al. in 1962, who reported a 'secondary disease' in mice after irradiation and infusion of allogeneic spleen cells. The disease manifested as fatal diarrhea and skin abnormalities. They postulated that aGVHD resulted from introducing immunologically competent cells into an immunocompetent host. Treatments were developed to address this problem, and most centers use calcineurin inhibitors (tacrolimus or cyclosporine) combined with mycophenolate mofetil or methotrexate to prevents aGVHD. This classic GVHD prophylaxis is associated with an incidence of acute GVHD of approximately sixty percent. Other methods of GVHD prevention, including T-cell depletion and more recently post-trasnplant cyclophosphamid, have been tested, but all have their own limitations. The most effective methods tend to be more immunosuppressive and are not clearly superior in regards to long-term survival. Acute GVHD then remains a major problem in hematopoietic stem cell allogeneic transplantation (HCT). Its initial treatment consists of high-dose glucocorticosteroids (1-2 mg/kg daily). However, only one-third of patients are cured, leaving the majority of patients requiring more therapy. Patients with glucocorticosteroid refractory acute GVHD (SR aGVHD) have a very high mortality and to date, there is no effective treatment.

journal_name

Leuk Lymphoma

journal_title

Leukemia & lymphoma

authors

Gergis U,van Besien K

doi

10.1080/10428194.2019.1613545

subject

Has Abstract

pub_date

2019-09-01 00:00:00

pages

2101-2103

issue

9

eissn

1042-8194

issn

1029-2403

journal_volume

60

pub_type

评论,杂志文章

相关文献

LEUKEMIA & LYMPHOMA文献大全
  • Involvement of tumor-associated macrophage activation in vitro during development of a novel mantle cell lymphoma cell line, PF-1, derived from a typical patient with relapsed disease.

    abstract：:Human mantle cell lymphoma (MCL) cell lines are scarce and have been only sporadically described and validated, and only a few have been thoroughly molecularly or genetically characterized. We describe here the successful establishment of a new MCL line, PF-1, with typical MCL characteristics. Culturing primary MCL ce...

    journal_title：Leukemia & lymphoma

    pub_type： 杂志文章

    doi：10.3109/10428194.2014.901511

    authors： Pham LV,Vang MT,Tamayo AT,Lu G,Challagundla P,Jorgensen JL,Rollo AA,Ou Z,Zhang L,Wang M,Ford RJ

    更新日期：2015-01-01 00:00:00

  • Systemic Irradiation Therapy of Myelomatosis-The Therapeutic Implications of Technique.

    abstract：:The pattern of disease relapse in nine patients with multiple myeloma who had received double hemi body irradiation therapy is analysed. This analysis highlights the localisation of these relapses to skeletal areas excluded from initial radiation fields. This phenomenon was also documented in a patient who received sy...

    journal_title：Leukemia & lymphoma

    pub_type： 杂志文章

    doi：10.3109/10428199009042484

    authors： Giles FJ,Lord CD,Gaminarai EJ,Grants IR,Kearney JW,Mills MJ,Newland AC,Nikoskelainen J,Pelliniemi T,Richards JD,Rostom AC,Tobias JS,Trask CT,Goldstone AH

    更新日期：1990-01-01 00:00:00

  • Joint occurrence of Merkel cell carcinoma and non-Hodgkin lymphomas in four Nordic countries.

    abstract：:The objective of this study was to assess the reciprocal association between non-Hodgkin lymphoma (NHL) and Merkel cell carcinoma (MCC) using the data of four Nordic Cancer Registries. Data for this study were drawn from the Danish, Finnish, Norwegian, and Swedish cancer registries. Standardized incidence ratios (SIRs...

    journal_title：Leukemia & lymphoma

    pub_type： 杂志文章

    doi：10.3109/10428194.2015.1040010

    authors： Koljonen V,Rantanen M,Sahi H,Mellemkjær L,Hansen BT,Chen T,Hemminki K,Pukkala E

    更新日期：2015-01-01 00:00:00

  • Megakaryocytic leukemia and platelet factor 4.

    abstract：:The de novo megakaryocytic leukemia fulfilling the FAB criteria is still an uncommonly recognized variant of acute leukemia. Many studies have shown that the megakaryocytic leukemic events may occur at a pluripotent stem cell level and clinical observations reveal that the megakaryocytic leukemias are diverse entities...

    journal_title：Leukemia & lymphoma

    pub_type： 杂志文章,评审

    doi：10.3109/10428199209051011

    authors： Ryo R,Yasunaga M,Saigo K,Yamaguchi N

    更新日期：1992-11-01 00:00:00

  • Vincristine but not imatinib could suppress mesenchymal niche's support to lymphoid leukemic cells.

    abstract：:Bone marrow mesenchymal stromal cells (MSCs) can rescue acute lymphoblastic leukemia (ALL) cells from L-asparaginase by replenishing the depleted asparagine. As both vincristine (VCR) and imatinib mesylate (IM) can inhibit MSCs' proliferation, we hypothesized that these drugs might reduce the niche support of MSCs to ...

    journal_title：Leukemia & lymphoma

    pub_type： 杂志文章

    doi：10.3109/10428190903406798

    authors： Fung KL,Liang RH,Chan GC

    更新日期：2010-03-01 00:00:00

  • Clofarabine: past, present, and future.

    abstract：:Clofarabine is a good generation purine nucleoside analogue designed to overcome the limitations and to incorporate the best qualities of both cladribine and fludarabine. Clofarabine is thought to work via three mechanisms: inhibition of ribonucleotide reductase; incorporation to DNA; and induction of apoptosis. Given...

    journal_title：Leukemia & lymphoma

    pub_type： 杂志文章,评审

    doi：10.1080/10428190701545644

    authors： Kantarjian HM,Jeha S,Gandhi V,Wess M,Faderl S

    更新日期：2007-10-01 00:00:00

  • Increased frequency of homozygosity for HLA class II loci in female patients with chronic lymphocytic leukemia.

    abstract：:The etiology of chronic lymphocytic leukemia (CLL) appears to be influenced by genetic factors which may contribute to its differential, gender- and age-specific incidence. The presented study is the first, which investigated the frequencies of DNA-typed alleles of all relevant human leukocyte antigens (HLA) loci in C...

    journal_title：Leukemia & lymphoma

    pub_type： 杂志文章

    doi：10.1080/10428190290021588

    authors： Mueller LP,Machulla HK

    更新日期：2002-05-01 00:00:00

  • Serum soluble interleukin-2 receptor levels in hairy cell leukemia: correlation with clinical and hematological parameters and with alpha-interferon treatment.

    abstract：:The soluble Interleukin-2 Receptor (sIL-2R) serum levels were assessed in 42 patients with Hairy-Cell Leukemia (HCL) at diagnosis and after alpha-Interferon therapy and correlated with spleen size, peripheral hematological values, hairy cell index (HCI) and clinical response. Serum sIL-2R levels were significantly inc...

    journal_title：Leukemia & lymphoma

    pub_type： 杂志文章

    doi：10.3109/10428199209053608

    authors： Lauria F,Rondelli D,Raspadori D,Zinzani PL,Benfenati D,Pileri S,Sabattini E,Tura S

    更新日期：1992-05-01 00:00:00

  • Primary granulocytic sarcoma of ovary--a rare presentation.

    abstract：:Granulocytic sarcomas (GS) are rare extra medullary tumors composed of myeloid progenitor cells. Bones, lymph nodes and skin are favored sites of involvement. Primary involvement of the ovary is exceedingly rare leading to under diagnosis of GS. We report on a 19-year-old woman who presented with an ovarian mass witho...

    journal_title：Leukemia & lymphoma

    pub_type： 杂志文章

    doi：10.1080/10428190312001623892

    authors： Mehta J,Kane S

    更新日期：2004-04-01 00:00:00

  • Graft-versus-host disease in mini-transplant.

    abstract：:Mini-transplant has been used popularly in recent years. The intensity of conditioning regimens is less in mini-transplant, thus the anti-tumor effect is mainly carried by an immunological reaction, called graft-versus-leukemia (GVL)/graft-versus-tumor (GVT) effect. Thus, graft-versus-host disease (GVHD) in mini-trans...

    journal_title：Leukemia & lymphoma

    pub_type： 杂志文章,评审

    doi：10.1080/1042819042000219511

    authors： Mineishi S,Schuening FG

    更新日期：2004-10-01 00:00:00

  • Familial Lymphoproliferative Disorders with Chromosomal Fragile Site Analysis.

    abstract：:We have identified a family in which three members developed B-cell lymphoproliferative disorders within a nine month period. The 33 year old proband and his mother have hairy cell leukemia, and his 37 year old brother developed a large cell lymphoma. Chromosomal fragile site analysis of peripheral blood lymphocytes o...

    journal_title：Leukemia & lymphoma

    pub_type： 杂志文章

    doi：10.3109/10428199109067623

    authors： Moormeier JA,Neilly ME,Vardiman JW,Le Beau MM,Golomb HM

    更新日期：1991-01-01 00:00:00

  • The impact of cell-of-origin, MYC/Bcl-2 dual expression and MYC rearrangement on disease relapse among early stage diffuse large B-cell lymphoma patients treated with combined modality therapy.

    abstract：:We addressed the prognostic impact of cell-of-origin (COO), MYC and Bcl-2 overexpression as well as isolated MYC rearrangement among 111 patients with limited stage diffuse large B-cell lymphoma (DLBCL) treated with consolidative radiation therapy (RT) after a metabolic complete response to immunochemotherapy. With a ...

    journal_title：Leukemia & lymphoma

    pub_type： 杂志文章

    doi：10.1080/10428194.2020.1869965

    authors： Augustyn A,Medeiros LJ,Ludmir EB,Gunther J,Fang P,Li S,Ok CY,Bankston ME,Verma V,Pasalic D,Ahmed S,Nastoupil LJ,Westin JR,Strati P,Neelapu SS,Nair R,Steiner RE,Iyer SP,Rodriguez A,Fayad LE,Flowers CR,Dabaja BS,

    更新日期：2021-01-22 00:00:00

  • AIDS-associated Burkitt or Burkitt-like lymphoma: short intensive polychemotherapy is feasible and effective.

    abstract：:The objective was to evaluate the feasibility and efficacy of a short-term, multi-agent and dose intensive regimen in AIDS patients with Burkitt or Burkitt-like lymphoma (BL/BLL) and to compare its efficacy with that of a conventional regimen. This was a retrospective, multi-center cohort study of all HIV-1-infected p...

    journal_title：Leukemia & lymphoma

    pub_type： 杂志文章,多中心研究

    doi：10.1080/10428190600685467

    authors： Hoffmann C,Wolf E,Wyen C,Fätkenheuer G,Van Lunzen J,Stellbrink HJ,Stoehr A,Plettenberg A,Jaeger H,Noppeney R,Hentrich M,Goekbuget N,Hoelzer D,Horst HA

    更新日期：2006-09-01 00:00:00

  • Novel therapies for myelofibrosis.

    abstract：:Myelofibrosis (MF), including primary, post-essential thrombocythemia and post-polycythemia vera MF, associates with a reduced quality of life and shortened life expectancy. Dysregulation of the Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway is prominent, even in the absence of the ...

    journal_title：Leukemia & lymphoma

    pub_type： 杂志文章,评审

    doi：10.3109/10428194.2015.1037762

    authors： Stein BL,Cervantes F,Giles F,Harrison CN,Verstovsek S

    更新日期：2015-01-01 00:00:00

  • Fas receptor (CD95)-mediated apoptosis in leukemic cells.

    abstract：:Binding of Fas ligand (FasL) or an agonistic anti-Fas receptor (Fas/CD95) antibody induces apoptosis in Fas-bearing target cells. The involvement of Fas/FasL pathway has been investigated in human acute myelogenous leukemia (AML) cells. Fas/CD95 is expressed on a majority of AML cells, although the intensity of expres...

    journal_title：Leukemia & lymphoma

    pub_type： 杂志文章,评审

    doi：10.3109/10428199709042492

    authors： Komada Y,Sakurai M

    更新日期：1997-03-01 00:00:00

  • Clonality assays and megakaryocyte culture techniques in essential thrombocythemia.

    abstract：:The development of techniques permitting in vitro growth of human megakaryocytes progenitors and more recently identification of the proto oncogene c-mpl (Mpl-R) and its ligand (Mpl-L) have created new opportunities for studying pathophysiology of E.T. Plasma or serum of E.T. patients was unable to overestimulate MK c...

    journal_title：Leukemia & lymphoma

    pub_type： 杂志文章,评审

    doi：10.3109/10428199609074358

    authors： Yan L,Elkassar N,Gardin C,Briere J

    更新日期：1996-09-01 00:00:00

  • Prognostic implications of extranodal involvement in patients with diffuse large B-cell lymphoma treated with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone.

    abstract：:The addition of rituximab (R) to standard CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) chemotherapy has altered the significance of previously recognized prognostic factors. We sought to re-examine the prognostic utility of (1) the number of extranodal sites of disease involvement, and (2) a prima...

    journal_title：Leukemia & lymphoma

    pub_type： 杂志文章

    doi：10.3109/10428194.2010.504872

    authors： Hui D,Proctor B,Donaldson J,Shenkier T,Hoskins P,Klasa R,Savage K,Chhanabhai M,Gascoyne RD,Connors JM,Sehn LH

    更新日期：2010-09-01 00:00:00

  • Clinical features and treatment of natural killer/T cell lymphoma associated with hemophagocytic syndrome: comparison with other T cell lymphoma associated with hemophagocytic syndrome.

    abstract：:Natural killer (NK)/T cell lymphoma associated with hemophagocytic syndrome (NK/T-LAHS) is a rare and life-threatening disease. The clinical features and overall survival of NK/T cell and other T cell lymphomas associated with hemophagocytic syndrome remain uncertain. We retrospectively reviewed the clinical records o...

    journal_title：Leukemia & lymphoma

    pub_type： 杂志文章

    doi：10.3109/10428194.2013.876629

    authors： Han L,Li L,Wu J,Li X,Zhang L,Wang X,Fu X,Ma W,Sun Z,Zhang X,Chang Y,Guo S,Zhang M

    更新日期：2014-09-01 00:00:00

  • CD31/PECAM-1 impacts engraftment, growth and spread of mantle cell lymphoma cells and positively correlates with extramedullary involvement.

    abstract：:Platelet/endothelial cell adhesion molecule 1 (PECAM-1, CD31) is an immunoglobulin superfamily member expressed on the surface of platelets, leukocytes and endothelial cells. The role of CD31 in biology of lymphomas has not yet been systemically studied. Expression of cell surface CD31 was analyzed by flow cytometry o...

    journal_title：Leukemia & lymphoma

    pub_type： 杂志文章

    doi：10.1080/10428194.2020.1849678

    authors： Vockova P,Molinsky J,Klanova M,Karban J,Spacek M,Havranek O,Kupcova K,Kazantsev D,Trneny M,Klener P

    更新日期：2020-11-25 00:00:00

  • Attempted reconstruction of the immune system using low doses of interleukin 2 in chronic lymphocytic leukemia patients treated with 2-chlorodeoxyadenosine: results of a pilot study.

    abstract：:This study was designed to investigate the immunostimulatory effect of low dose Il-2 treatment in B-CLL patients previously treated with 2-chlorodeoxyadenosine (2CdA) in whom severe depletion of T lymphocyte subsets was observed. Four patients enrolled into the study had previously been treated with 3-6 courses of 2Cd...

    journal_title：Leukemia & lymphoma

    pub_type： 临床试验,杂志文章

    doi：10.3109/10428199909050958

    authors： Dmoszyńska A,Legiec W,Wach M

    更新日期：1999-07-01 00:00:00

  • Vincristine degradation by serum from leukemic patients: role of myeloperoxidase.

    abstract：:Myeloperoxidase (MPO) has been shown to catalyze the in vitro degradation of vincristine (VCR). Given that MPO is a lysosomal enzyme that can be released into the circulation by both normal activated and leukemic myeloid cells, we investigated the possibility that sera from patients with acute myeloblastic leukemia (A...

    journal_title：Leukemia & lymphoma

    pub_type： 杂志文章

    doi：10.3109/10428199609052426

    authors： Schlaifer D,Duchayne E,Demur C,Alvinerie P,Muller C,Attal M,Cooper MR,Payen C,Monsarrat B,Myers CE,Pris J,Laurent G

    更新日期：1996-02-01 00:00:00

  • Amifostine reduces gastro-intestinal toxicity after autologous transplantation for multiple myeloma.

    abstract：:High-dose melphalan (HDM) followed by autologous hematopoietic cell transplantation (auto-HCT) remains the standard-of-care therapy for multiple myeloma (MM) even with the availability of proteasome inhibitors and immunomodulatory drugs. Gastrointestinal (GI) toxicity is the main cause of morbidity after HDM. Amifosti...

    journal_title：Leukemia & lymphoma

    pub_type： 杂志文章

    doi：10.1080/10428194.2017.1408086

    authors： Malek E,Gupta V,Creger R,Caimi P,Vatsayan A,Covut F,Bashir Q,Champlin R,Delgado R,Rondon G,Cooper B,de Lima M,Lazarus HM,Qazilbash M

    更新日期：2018-08-01 00:00:00

  • Fixed-dose pegfilgrastim is safe and allows neutrophil recovery in patients with non-Hodgkin's lymphoma.

    abstract：:Twenty-nine patients with non-Hodgkin's lymphoma received a single subcutaneous injection of 6 mg pegfilgrastim approximately 24 h after the start of CHOP chemotherapy. The safety of pegfilgrastim in this patient population was determined by reports of adverse events. The pharmacokinetics of pegfilgrastim were charact...

    journal_title：Leukemia & lymphoma

    pub_type： 杂志文章,多中心研究

    doi：10.1080/1042819031000063462

    authors： George S,Yunus F,Case D,Yang BB,Hackett J,Shogan JE,Meza LA,Neumann TA,Liang BC

    更新日期：2003-10-01 00:00:00

  • Dual expression of MYC and BCL2 proteins predicts worse outcomes in diffuse large B-cell lymphoma.

    abstract：:Recent studies suggested that MYC and BCL2 protein co-expression is an independent indicator of poor prognosis in diffuse large B-cell lymphoma. However, the immunohistochemistry protocols for dual-expression staining and the scoring cut-offs vary by study. Sixty-nine cases of diffuse large B-cell lymphoma were evalua...

    journal_title：Leukemia & lymphoma

    pub_type： 杂志文章

    doi：10.3109/10428194.2015.1101099

    authors： Clark Schneider KM,Banks PM,Collie AM,Lanigan CP,Manilich E,Durkin LM,Hill BT,Hsi ED

    更新日期：2016-07-01 00:00:00

  • Increased circulating CD3+ T cells are associated with early relapse following autologous hematopoietic stem cell transplantation in patients with classical Hodgkin lymphoma.

    abstract：:Non-malignant host immune cells are the main substrate in classical Hodgkin lymphoma (HL) microenvironment. Reconstitution of lymphocyte populations following the high-dose chemotherapy (HDC) with autologous hematopoietic stem cell transplantation (auto-HSCT) can support tumor growth in HL patients. We investigated re...

    journal_title：Leukemia & lymphoma

    pub_type： 杂志文章

    doi：10.1080/10428194.2019.1581934

    authors： Batorov EV,Pronkina NV,Tikhonova MA,Kryuchkova IV,Sergeevicheva VV,Sizikova SA,Ushakova GY,Aristova TA,Batorova DS,Shishkova IV,Gilevich AV,Shevela EY,Ostanin AA,Chernykh ER

    更新日期：2019-10-01 00:00:00

  • Intrathecal therapy with rituximab in central nervous system involvement of post-transplant lymphoproliferative disorder.

    abstract：:Post-transplant lymphoproliferative disorder (PTLD) caused by Epstein-Barr virus (EBV) is a severe complication in high-risk allogeneic hematopoietic stem cell transplant (HSCT) recipients. Central nervous system (CNS) involvement of PTLD is a very rare event in patients with HSCT. As no established standard therapy i...

    journal_title：Leukemia & lymphoma

    pub_type： 临床试验,杂志文章

    doi：10.3109/10428194.2012.718342

    authors： Czyzewski K,Styczynski J,Krenska A,Debski R,Zajac-Spychala O,Wachowiak J,Wysocki M

    更新日期：2013-03-01 00:00:00

  • Invasive mold infections: recent advances in management approaches.

    abstract：:An increasing number of patients are undergoing transplantation procedures or receiving aggressive immunosuppression and chemotherapy. The growing population of immunocompromised hosts has led to a rise in the prevalence of invasive fungal infections (IFIs) due to yeasts and molds. Recent trends suggest that patients ...

    journal_title：Leukemia & lymphoma

    pub_type： 杂志文章,评审

    doi：10.1080/10428190902777434

    authors： Chandrasekar P

    更新日期：2009-05-01 00:00:00

  • Effects of induction with novel agents versus conventional chemotherapy on mobilization and autologous stem cell transplant outcomes in multiple myeloma.

    abstract：:Multiple myeloma (MM) is the top indication for high-dose chemotherapy (HDC) with autologous stem cell transplantation (SCT), a strategy which improves progression-free survival and potentially overall survival (OS). Novel induction regimens incorporating the immunomodulatory (IMID) agents, such as thalidomide and len...

    journal_title：Leukemia & lymphoma

    pub_type： 杂志文章

    doi：10.3109/10428190903480728

    authors： Benson DM Jr,Panzner K,Hamadani M,Hofmeister CC,Bakan CE,Smith MK,Elder P,Krugh D,O'Donnell L,Devine SM

    更新日期：2010-02-01 00:00:00

  • Combination of the dual PIM/PI3-kinase inhibitor IBL-202 and venetoclax is effective in diffuse large B-cell lymphoma.

    abstract：:Current chemoimmunotherapy is unable to cure up to 40% of patients diagnosed with diffuse large B-cell lymphoma (DLBCL). Targeting the mechanisms by which DLBCL evades apoptosis is crucial to overcoming treatment failure in this heterogeneous disease as both current and novel treatments depend on the apoptosis of mali...

    journal_title：Leukemia & lymphoma

    pub_type： 杂志文章

    doi：10.1080/10428194.2020.1795156

    authors： Gifford G,Stevenson W,Best G

    更新日期：2020-12-01 00:00:00

  • Report on the First International Workshop on Interim-PET-Scan in Lymphoma.

    abstract：:An international workshop, under the auspices of Group d'Etude des Lymphomes de l'Adulte (GELA) took place in Deauville, France, in April 3-4, 2009. The European experts with a published or personal experience on interim-PET in lymphoma were invited to the meeting. The aim of the workshop was twofold: (1) to reach a c...

    journal_title：Leukemia & lymphoma

    pub_type：

    doi：10.1080/10428190903040048

    authors： Meignan M,Gallamini A,Meignan M,Gallamini A,Haioun C

    更新日期：2009-08-01 00:00:00